Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ABGSC Life Science Summit...
Read moreMedivir Aktiebolag (publ) held its annual shareholders’ meeting today on 5 May 2022. The annual general meeting was held by physical...
Read moreMomentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – March Financial summary for the...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the Kempen Life Sciences Conference,...
Read moreStockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the...
Read moreThe shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an article entitled “Symptomatic and structural benefit of cathepsin K...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its new CEO Jens Lindberg will participate at the Erik...
Read moreOctober – December Financial summary for the quarter Net turnover amounted to SEK 13.9 (1.5) million. The loss before interest, tax,...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Liver biopsy biomarkers in a phase 1...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the World Health Organization (WHO) has selected the International Nonproprietary...
Read more